What is GIP?
GIP stands for glucose-dependent insulinotropic polypeptide, a naturally occurring peptide hormone involved in the body's response to nutrients. It is one of the two principal incretin hormones, alongside glucagon-like peptide-1 (GLP-1).
GIP is released primarily from specialised enteroendocrine K cells following food intake. One of its best-established physiological functions is enhancing insulin secretion when blood glucose is elevated. Research also investigates GIP signalling in adipose tissue, bone, the nervous system and broader metabolic regulation.
Historical meaning and modern name
GIP was originally called gastric inhibitory polypeptide because early experiments suggested that it could reduce gastric acid secretion.
Subsequent research demonstrated that stimulation of glucose-dependent insulin secretion was a more prominent physiological function. The same abbreviation was therefore retained while the name glucose-dependent insulinotropic polypeptide became widely adopted.
Both names can consequently appear in older and modern scientific literature, but they refer to the same peptide hormone.
Incretin biology
The incretin effect describes the greater insulin response generally observed when glucose is consumed orally compared with an equivalent glucose exposure delivered directly into the circulation.
Hormones released from the gastrointestinal tract help produce this difference. GIP and GLP-1 are the two major recognised incretin hormones.
Following nutrient intake, GIP enters the circulation and interacts with receptors on pancreatic beta cells. When glucose concentrations are elevated, this signalling enhances insulin secretion and helps coordinate nutrient availability with pancreatic endocrine responses.
GIP receptor
The GIP receptor, abbreviated GIPR, is a G-protein-coupled receptor activated by GIP. It is expressed in pancreatic beta cells and several other tissues.
GIPR activation commonly stimulates intracellular pathways involving cyclic AMP (cAMP), which contributes to glucose-dependent insulin secretion in pancreatic beta cells.
Research has also identified GIP receptors in tissues outside the pancreas, leading to investigation of GIP signalling in adipose biology, bone metabolism and the nervous system. The physiological significance of these pathways varies and remains an active area of research.
Metabolic signalling
GIP secretion is stimulated by nutrient intake, including carbohydrates and fats, making it part of the communication network connecting the gastrointestinal tract with metabolic tissues.
Its established role in pancreatic insulin secretion is only one component of this biology. Researchers have also investigated GIP signalling in lipid metabolism, adipose tissue and energy regulation.
These pathways are complex. The effects of natural GIP cannot be reduced to a simple description such as promoting or preventing fat storage, because outcomes depend on nutritional state, receptor signalling and interactions with other metabolic hormones.
GIP vs GLP-1
GIP and GLP-1 are both incretin hormones, but they are separate peptides produced predominantly by different enteroendocrine cell populations and acting through different receptors.
GIP is primarily secreted by K cells, particularly in the proximal small intestine, and activates the GIP receptor. GLP-1 is produced predominantly by intestinal L cells and activates the GLP-1 receptor.
Both can enhance glucose-dependent insulin secretion. GLP-1 additionally has well-established effects involving glucagon regulation, gastric emptying and appetite-related signalling.
Their overlapping but distinct physiology has led to pharmaceutical research investigating simultaneous activation of both receptor systems.
Relationship to tirzepatide
Tirzepatide is a synthetic peptide-based medicine designed to activate both GIP and GLP-1 receptors. It is therefore commonly described as a dual GIP/GLP-1 receptor agonist.
This is different from natural GIP. Tirzepatide has been molecularly engineered to produce prolonged pharmacological receptor activation and has properties that differ substantially from endogenous incretin hormones.
Clinical findings involving tirzepatide therefore belong specifically to tirzepatide and should not automatically be interpreted as evidence for administering GIP itself.
Relationship to retatrutide
Retatrutide is an investigational peptide designed to activate three metabolic receptor systems: GIP, GLP-1 and glucagon receptors.
Its GIP-receptor activity therefore represents only one component of its pharmacology. Simultaneous activation of three receptor systems produces a fundamentally different experimental intervention from natural GIP signalling or a compound targeting GIPR alone.
Research findings involving retatrutide should consequently be attributed to the complete molecule rather than described simply as effects of GIP.
Frequently asked questions
What does GIP stand for?
GIP most commonly stands for glucose-dependent insulinotropic polypeptide. Historically, it was known as gastric inhibitory polypeptide.
Is GIP naturally produced by humans?
Yes. GIP is an endogenous peptide hormone released primarily from enteroendocrine K cells following nutrient intake.
Is GIP an incretin?
Yes. GIP and GLP-1 are the two principal recognised incretin hormones.
What does GIP do?
One of its best-established functions is enhancing glucose-dependent insulin secretion following nutrient intake. It also participates in broader metabolic signalling.
Is GIP the same as GLP-1?
No. They are separate incretin hormones acting through different receptors, although both contribute to glucose-dependent insulin secretion.
Is GIP the same as tirzepatide?
No. Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist engineered for prolonged pharmacological activity.
Does retatrutide target GIP receptors?
Yes. Retatrutide is being investigated as a triple agonist targeting GIP, GLP-1 and glucagon receptors.
Can results from tirzepatide or retatrutide be attributed to GIP alone?
No. Both compounds engage multiple receptor systems, so their clinical or experimental effects cannot be assigned solely to GIP signalling.
Scientific references
Scientific literature on GIP includes extensive research into incretin physiology, intestinal K-cell secretion, GIP receptor signalling, pancreatic beta-cell function and broader metabolic biology. Studies involving tirzepatide and retatrutide should be evaluated separately because these engineered molecules activate multiple receptor systems and have pharmacological properties substantially different from endogenous GIP.